State Street
PHAT icon

State Street’s Phathom Pharmaceuticals PHAT Stock Holding History

State Street’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Buy
1,586,323
+199,433
+14% +$2.28M ﹤0.01% 2435
2026
Q1 		$15.4M Buy
1,386,890
+237,354
+21% +$3M ﹤0.01% 2379
2025
Q4 		$19.1M Buy
1,149,536
+95,945
+9% +$1.37M ﹤0.01% 2294
2025
Q3 		$12.4M Buy
1,053,591
+204,167
+24% +$2.11M ﹤0.01% 2518
2025
Q2 		$8.15M Sell
849,424
-51,930
-6% -$287K ﹤0.01% 2708
2025
Q1 		$5.65M Sell
901,354
-138,582
-13% -$841K ﹤0.01% 2827
2024
Q4 		$8.44M Buy
1,039,936
+117,148
+13% +$1.45M ﹤0.01% 2720
2024
Q3 		$16.7M Buy
922,788
+137,539
+18% +$1.92M ﹤0.01% 2320
2024
Q2 		$8.09M Buy
785,249
+68,048
+9% +$701K ﹤0.01% 2688
2024
Q1 		$7.62M Buy
717,201
+29,364
+4% +$249K ﹤0.01% 2734
2023
Q4 		$6.28M Buy
687,837
+20,241
+3% +$174K ﹤0.01% 2847
2023
Q3 		$6.92M Buy
667,596
+137,753
+26% +$1.89M ﹤0.01% 2766
2023
Q2 		$7.59M Buy
529,843
+66,100
+14% +$762K ﹤0.01% 2792
2023
Q1 		$3.31M Buy
463,743
+12,394
+3% +$109K ﹤0.01% 3144
2022
Q4 		$5.06M Buy
451,349
+5,854
+1% +$60.3K ﹤0.01% 3038
2022
Q3 		$4.94M Buy
445,495
+36,613
+9% +$349K ﹤0.01% 3067
2022
Q2 		$3.45M Buy
408,882
+43,838
+12% +$451K ﹤0.01% 3278
2022
Q1 		$4.97M Buy
365,044
+23,104
+7% +$373K ﹤0.01% 3183
2021
Q4 		$6.73M Sell
341,940
-12,824
-4% -$302K ﹤0.01% 3109
2021
Q3 		$11.4M Buy
354,764
+14,461
+4% +$481K ﹤0.01% 2811
2021
Q2 		$11.5M Buy
340,303
+123,105
+57% +$4.41M ﹤0.01% 2831
2021
Q1 		$8.16M Buy
217,198
+8,148
+4% +$341K ﹤0.01% 2834
2020
Q4 		$6.95M Sell
209,050
-5,257
-2% -$213K ﹤0.01% 2805
2020
Q3 		$7.86M Buy
214,307
+1,500
+0.7% +$51.9K ﹤0.01% 2568
2020
Q2 		$7M Buy
212,807
+25,499
+14% +$980K ﹤0.01% 2597
2020
Q1 		$4.84M Buy
187,308
+62,065
+50% +$2.07M ﹤0.01% 2644
2019
Q4 		$3.9M Buy
+125,243
New +$3.15M ﹤0.01% 2957

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street's PHAT Position: Q2 2026 in Review

State Street increased its Phathom Pharmaceuticals (PHAT) stake by 14% in Q2 2026, buying an estimated $2.28M and bringing the position to 1,586,323 shares worth $17.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2435.

State Street first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $19.1M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • State Street held 1,586,323 shares of Phathom Pharmaceuticals worth $17.2M as of Q2 2026.
  • State Street bought 199,433 Phathom Pharmaceuticals shares in Q2 2026, an estimated $2.28M.
  • Phathom Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2435 holding.
  • State Street first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • State Street's Phathom Pharmaceuticals position peaked at $19.1M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.